Go to the list of all blogs
Anna G's Avatar
published in Blogs
Sep 16, 2023
📈Akoustis Technologies (AKTS): Volume Soars with +244% 5-Day Streak! What’s Behind the Surge?🚀

📈Akoustis Technologies (AKTS): Volume Soars with +244% 5-Day Streak! What’s Behind the Surge?🚀

🚀 Ready to Dive into AI-Powered Trading? Discover the Top 10 AI Robots! 📊

 if you're interested in AI trading and want to explore the top 10 AI robots, you can find them at the following links:

  1. Top 10 AI Robots  - SORT BY Sharper 
  2. Top 10 AI Robots  - SORT BY  30-day Annualized Return
  3. Top 10 AI Robots  - SORT BY  All Time Annualized Return

These AI robots are designed to provide insights and strategies to enhance your trading experience. Feel free to explore them and discover how AI can empower your trading decisions. 🤖📈

Akoustis Technologies

$AKTS has been making waves in the stock market lately, especially with its notable volume surge. Over the past five consecutive days, AKTS has seen an impressive average daily volume gain of 244%. Despite the broader Telecommunications Equipment industry trending downwards, this stock has drawn considerable attention from investors and traders alike.

📊Volume vs. Price Dynamics

The stock's volume momentum contrasts with its recent price performance. AKTS experienced a price decline of -39.05%, settling at $0.92. Such a divergence between volume and price could suggest a potential trend reversal, making it an enticing buy signal for some investors. Historical data seems to support this bullish view: A.I.dvisor's analysis of 48 similar volume-price patterns in the past found that 39 (or 81%) were followed by positive price movements.

🔢Earnings Report

However, it’s crucial to factor in the company’s recent earnings report from September 06. AKTS reported an earnings per share (EPS) of -20 cents, falling short of the estimated -16 cents. The firm’s current market capitalization stands at 75.25M, backed by 2.41M shares outstanding.

🌐Industry Overview

AKTS is nestled within the Telecommunications Equipment industry, which has been grappling with an average weekly price decline of -1%. This industry is responsible for producing a myriad of critical communications equipment, from fiber optic products to satellite systems. Titans in this space include Cisco Systems, Nokia Corp, and Apple Inc., amongst others.

💹Market Capitalization Insights

The Telecommunications Equipment Industry has a broad market cap spectrum, ranging from a meager 1.59K to a whopping 229.87B. Unsurprisingly, Cisco Systems (CSCO) claims the throne with the highest valuation, whereas ABILF stands at the other end of the spectrum.

📉Recent Performance

The last five trading days for AKTS weren't too rosy, with the stock shedding -16.34%. This was accompanied by a trade volume of approximately 285,696 shares daily. A significant drawdown of -36.05% was observed during this period.

While Akoustis Technologies has experienced a dip in its stock price, the explosive volume could hint at a turning point. As always, investors should conduct their due diligence and factor in both the micro and macroeconomic elements before making investment decisions.

Join us next week as we dive deeper into the intricacies of the Telecommunications Equipment industry and explore potential hidden gems!

Related Ticker: AKTS

AKTS in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 11, 2026

AKTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 33 cases where AKTS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKTS advanced for three days, in 174 of 207 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKTS as a result. In 56 of 63 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for AKTS turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 31 similar instances when the indicator turned negative. In 27 of the 31 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

AKTS moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AKTS crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for AKTS entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AKTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.220) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (438.009).

The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 58 to 133.74B. VRTX holds the highest valuation in this group at 133.74B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -4%. LONA experienced the highest price growth at 64%, while AVBP experienced the biggest fall at -49%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -2%. For the same stocks of the Industry, the average monthly volume growth was 61% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
AKTS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of filter products for radio frequency front-ends for mobile wireless devices

Industry Biotechnology

Industry
Telecommunications Equipment
Address
17 Drydock Avenue
Phone
+1 617 461-4023
Employees
75
Web
https://www.aktisoncology.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.